Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 02, 2023

BUY
$0.39 - $0.71 $198 - $362
510 Added 2.47%
21,185 $8,000
Q4 2022

Feb 09, 2023

SELL
$0.33 - $10.44 $2 - $83
-8 Reduced 0.04%
20,675 $8,000
Q3 2022

Nov 02, 2022

SELL
$0.92 - $11.16 $3,611 - $43,814
-3,926 Reduced 15.95%
20,683 $18,000
Q2 2022

Aug 01, 2022

BUY
$1.02 - $1.83 $395 - $710
388 Added 1.6%
24,609 $29,000
Q1 2022

May 04, 2022

SELL
$1.06 - $2.1 $732 - $1,451
-691 Reduced 2.77%
24,221 $34,000
Q4 2021

Feb 07, 2022

SELL
$2.05 - $3.2 $1,176 - $1,836
-574 Reduced 2.25%
24,912 $51,000
Q3 2021

Nov 02, 2021

BUY
$2.54 - $4.07 $744 - $1,192
293 Added 1.16%
25,486 $78,000
Q2 2021

Aug 03, 2021

SELL
$2.57 - $4.85 $1,179 - $2,226
-459 Reduced 1.79%
25,193 $103,000
Q1 2021

May 04, 2021

SELL
$1.9 - $2.82 $1,516 - $2,250
-798 Reduced 3.02%
25,652 $63,000
Q4 2020

Feb 01, 2021

BUY
$1.15 - $2.4 $1,282 - $2,676
1,115 Added 4.4%
26,450 $56,000
Q3 2020

Nov 09, 2020

SELL
$1.11 - $1.68 $697 - $1,055
-628 Reduced 2.42%
25,335 $31,000
Q2 2020

Aug 07, 2020

BUY
$1.69 - $4.2 $2,408 - $5,985
1,425 Added 5.81%
25,963 $45,000
Q1 2020

May 04, 2020

BUY
$1.26 - $3.38 $15,317 - $41,090
12,157 Added 98.19%
24,538 $65,000
Q4 2019

Feb 04, 2020

BUY
$0.86 - $1.44 $694 - $1,163
808 Added 6.98%
12,381 $23,000
Q3 2019

Nov 12, 2019

BUY
$1.21 - $1.59 $14,003 - $18,401
11,573 New
11,573 $14,000
Q4 2018

Feb 05, 2019

SELL
$3.23 - $7.01 $668,610 - $1.45 Million
-207,000 Closed
0 $0
Q3 2018

Nov 01, 2018

SELL
$6.86 - $9.97 $304,309 - $442,269
-44,360 Reduced 17.65%
207,000 $1.5 Million
Q2 2018

Aug 02, 2018

SELL
$2.88 - $8.67 $64,656 - $194,641
-22,450 Reduced 8.2%
251,360 $1.73 Million
Q1 2018

May 04, 2018

BUY
$2.92 - $3.81 $799,525 - $1.04 Million
273,810 New
273,810 $816,000

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $1.09B
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.